(Q37689179)

22 August 2017

1 reference

title

The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant (English)

1 reference

22 August 2017

Amin M Alousi

1

1 reference

22 August 2017

Joseph Uberti

series ordinal

2

1 reference

22 August 2017

Voravit Ratanatharathorn

series ordinal

3

1 reference

22 August 2017

language of work or name

1 reference

8 February 2010

1 reference

22 August 2017

1 reference

22 August 2017

51

1 reference

22 August 2017

3

1 reference

22 August 2017

376-389

1 reference

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation

22 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Rituximab for steroid-refractory chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Identification of a graft versus host disease-associated human minor histocompatibility antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Pathophysiology of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Murine models of chronic graft-versus-host disease: insights and unresolved issues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

GVHD pathophysiology: is acute different from chronic?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

The role of CD40 ligand in costimulation and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. II. Anti-mu treatment affects the initiation and recruitment of T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Splenic B cells function as immunogenic antigen-presenting cells for the induction of effector T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Identification of two subpopulations of purified human blood B cells, CD27- CD23+ and CD27high CD80+, that strongly express cell surface Toll-like receptor 9 and secrete high levels of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

BAFF: a fundamental survival factor for B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

High levels of B-cell activating factor in patients with active chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Mouse CD20 expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Isolation and characterization of the B-cell marker CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Pharmacokinetics of rituximab and its clinical use: thought for the best use?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Newer monoclonal antibodies for hematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

B cells move to centre stage: novel opportunities for autoimmune disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Molecular framework for response to imatinib mesylate in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

Altered Toll-Like Receptor 9 Responses in Circulating B Cells at the Onset of Extensive Chronic Graft-versus-Host Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903586318

10.3109/10428190903586318

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference